In back-to-back trial disasters, Gemphire now says it shuttered a trial after seeing patients' fatty liver disease get worse
Four days after Gemphire saw its shares $GEMP crushed by news of an FDA demand for additional safety data on its only drug before advancing it into Phase III, the biotech is back with more bad, terrible, absolutely no good news.
A Phase IIa study for gemcabene in pediatric patients with non-alcoholic fatty liver disease, or NAFLD, has been scrapped after investigators determined that the first three patients got worse after being dosed. And another mid-stage study is under close review to see if the biotech needs to shutter it as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.